Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Novartis’ gene therapy treatment for spinal muscular atrophy could receive marketing approval as early as May 2019 after the U.S. Food and Drug Administration granted AVXS-101, now dubbed Zolgensma, priority review.
Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.
Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.
German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.
San Mateo, Calif.-based startup CuraSen Therapeutics surged forward with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.
Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.
Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.